Journal article
Higher-risk APS: do we dare to DOAC?
Abstract
In this issue of Blood, Pengo et al present a randomized control trial comparing the use of rivaroxaban and warfarin in high-risk patients with antiphospholipid antibody syndrome (APS). The trial was stopped early because of an increased number of events in the rivaroxaban arm.1
Authors
Laureano M; Crowther MA
Journal
Blood, Vol. 132, No. 13, pp. 1357–1358
Publisher
American Society of Hematology
Publication Date
September 27, 2018
DOI
10.1182/blood-2018-08-867036
ISSN
0006-4971